<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347929</url>
  </required_header>
  <id_info>
    <org_study_id>SO-2017-1</org_study_id>
    <secondary_id>2014-003623-21</secondary_id>
    <nct_id>NCT03347929</nct_id>
  </id_info>
  <brief_title>NSAIDs in Sciatica NSAIDS IN SCIATICA</brief_title>
  <acronym>NIS</acronym>
  <official_title>NSAIDs in Sciatica (NIS), an Investigator Initiated Randomised Placebo Controlled Trial of Naproxen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ostfold Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sykehuset Telemark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ostfold Hospital Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate whether treatment with Naproxen 500 mg twice daily is superior to
      placebo for the improvement of leg pain in patients with sciatica. Half of patients will
      receive Naproxen while the other half will receive placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sciatica is an established term for pain radiating from the lower back or buttock into the
      leg, commonly caused by a disc herniation. Given their analgesic and anti-inflammatory
      mechanisms of action, NSAIDs (Non-steroidal anti-inflammatory drugs) have been, and are still
      being regarded as standard therapy for sciatica.

      However, very few randomised controlled trials of NSAIDs have been undertaken in sciatica,
      and no study has showed clinically meaningful effects as compared to placebo.

      Since NSAIDs involve the risk of serious gastrointestinal, vascular and renal side effects
      there is a strong need to clarify their potential beneficial effects in sciatica.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 30, 2017</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leg pain</measure>
    <time_frame>Daily from baseline to day10</time_frame>
    <description>A 0-10 numeric rating scale of average leg pain intensity in the previous 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Back pain</measure>
    <time_frame>Daily from baseline to day10</time_frame>
    <description>24 h average back pain will be assessed by a 0-10 numeric rating scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability</measure>
    <time_frame>Day 0, day 5, day, day 10, day 12</time_frame>
    <description>Roland Morris Disability Questionnaire modified for use in sciatica</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sciatica symptoms</measure>
    <time_frame>Day 0, day 5, day, day 10, day 12</time_frame>
    <description>Sciatica Bothersomeness Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work</measure>
    <time_frame>Day 0, day 10, day 12</time_frame>
    <description>Ability to work and study as normal</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement</measure>
    <time_frame>Day 5, day 10</time_frame>
    <description>Global perceived change of sciatica/back problem on a verbal rating scale (Completely gone, much better, better, a little better, no change, a little worse, worse and much worse).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rescue medication</measure>
    <time_frame>Daily from day1 to day10</time_frame>
    <description>Intake of Paracetamol 500 mg tablets (rescue medication) for pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid medication</measure>
    <time_frame>Daily from day1 to day10</time_frame>
    <description>Intake of opioid medication (weak or strong) for pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responder</measure>
    <time_frame>Day 5, day 10</time_frame>
    <description>&gt;30% and &gt;50% reduction in leg pain relative to baseline</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Sciatica</condition>
  <arm_group>
    <arm_group_label>Naproxen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Naproxen 500 mg twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo 1 tablet twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naproxen 500 Mg</intervention_name>
    <description>10 days treatment with Naproxen 500 mg twice daily</description>
    <arm_group_label>Naproxen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 days treatment with Placebo1 tablet twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Age ≥ 18 years

          -  Radiating pain below the knee with a severity score of ≥4 on a 0-10 (NRS) in the
             previous 24 hours

          -  Signs of nerve root/spinal nerve involvement as indicated by at least one of the
             following features; myotomal weakness, dermatomal sensory disturbances (e.g. sensory
             loss, self-reported tingling/numbness), diminished reflexes, radiating pain
             exacerbation by SLR

        Exclusion criteria:

          -  Not able to read or speak Norwegian.

          -  Unlikely to adhere to treatment and/ or complete follow-up (e.g ongoing serious
             psychiatric disease, drug abuse, plans to move)

          -  Sciatica of known cause other than disc herniation or degenerative stenosis.

          -  Neurogenic claudication, i.e. pain in the legs on walking or standing that resolves
             with sitting down or lumbar flexion.

          -  Symptoms indicating immediate surgery: cauda equina syndrome or a progressive large
             paresis.

          -  Women who attempt to conceive, are pregnant or breastfeeding.

          -  Previous episodes of asthma, urticaria or allergic-type reactions after taking aspirin
             or other NSAIDs.

          -  Active or history of peptic ulceration, gastrointestinal bleeding, or perforation.

          -  Use of drugs known to increase upper gastrointestinal adverse events in combination
             with Naproxen: anticoagulants, aspirin (acetyl salicylic acid), serotonin reuptake
             inhibitors and systemic corticosteroids.

          -  Hepatic enzyme (ASAT/ALAT) values above 1,5 x upper limit of normal (ULN)

          -  Renal function tests (creatinin/eGFR) outside normal range

          -  Congestive heart failure, established ischaemic heart disease, peripheral arterial
             disease, and/or cerebrovascular disease.

          -  Known hypersensitivity to Naproxen or any of the excipients (lactose, maize starch,
             povidone, sodium starch glycolate, talcum, magnesium stearate, polysorbate 80)

          -  Ongoing treatment with aspirin, systemic corticosteroids, diuretics, ACE-inhibitors,
             lithium and anticoagulants

          -  Scheduled for spinal surgery prior to end of study

          -  Reservation against intake of gelatine (the capsules contains gelatine, which among
             other things is produced by ingredients from pigs)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waleed Ghanima, MD,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Ostfold Hospital Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Haugen, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ostfold Hospital Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne J Haugen, MD,PhD</last_name>
    <phone>+4791193452</phone>
    <email>annhau@so-hf.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lars Grøvle, MD,PhD</last_name>
    <phone>+4791814029</phone>
    <email>largro@so-hf.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seksjon for fysikalsk medisin og rehabilitering, Drammen Sykehus, Vestre Viken</name>
      <address>
        <city>Drammen</city>
        <zip>3004</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Froholdt, MD,PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Revmatologisk avdeling, Sykehuset Østfold Moss</name>
      <address>
        <city>Moss</city>
        <zip>1714</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne J Haugen, MD,PhD</last_name>
      <phone>+4791193452</phone>
      <email>annhau@so-hf.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fysikalsk medisinsk poliklinikk, Sykehuset Telemark</name>
      <address>
        <city>Porsgrunn</city>
        <zip>3710</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anders Sætre, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Avdeling for fysikalsk medisin og rehabilitering, Stavanger Universitetssjukehus</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ståle Mathiassen, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>November 17, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sciatica</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

